Trials / Completed
CompletedNCT02531438
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 774 (actual)
- Sponsor
- Paratek Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omadacycline | Injection for IV; Oral tablets |
| DRUG | Moxifloxacin | IV solution; Oral tablets |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2017-02-05
- Completion
- 2017-03-10
- First posted
- 2015-08-24
- Last updated
- 2019-01-16
- Results posted
- 2018-11-29
Locations
140 sites across 25 countries: United States, Belgium, Brazil, Bulgaria, Croatia, Czechia, Georgia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine
Source: ClinicalTrials.gov record NCT02531438. Inclusion in this directory is not an endorsement.